R3 Vascular Inc.

R3 Vascular Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

R3 Vascular is a privately-held Medical Device company that has created a novel technology platform for developing and manufacturing fully bioresorbable vascular scaffolds (BVS) with a sirolimus coating for the treatment of peripheral artery disease (PAD) below the knee. PAD is the narrowing or blockage of the vessels that carry blood from the heart to the legs or lower extremities; it is primarily caused by the buildup of fatty plaque in the arteries, which is called atherosclerosis. PAD can happen in any blood vessel, but it is more common in the legs than the arms. It affects 200 million people globally. Approximately 6.5 million people at the age of 40 and older in the United States have PAD. These numbers continue to rise given the increasing burden of risk factors and an aging population. If a patient has PAD, they are at risk for developing coronary artery disease and cerebrovascular disease, which could lead to a heart attack or stroke as well. The R3 Vascular BVS platform combines the best of both worlds of BTK therapy, designed to deliver the ‘stent-like’ support of a scaffold, along with the anti-inflammatory result of sirolimus, but ‘disappearing’ over time as the vessel heals. R3 Vascular is headquartered in Mountain View, Calif., USA, with additional operations in Munich, Germany.

Company Details

Employees
25
Address
1145 Terra Bella Ave, Mountain View,california 94043,united States
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Mountain View, California
Looking for a particular R3 Vascular Inc. employee's phone or email?

R3 Vascular Inc. Questions

News

R3 Vascular Receives WGC IRB Approval for its ELITE-BTK Pivotal Trial of its Next Generation Bioresorbable Scaffold - Diagnostic and Interventional Cardiology

R3 Vascular Receives WGC IRB Approval for its ELITE-BTK Pivotal Trial of its Next Generation Bioresorbable Scaffold Diagnostic and Interventional Cardiology

R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold - GlobeNewswire

R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold GlobeNewswire

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial - Diagnostic and Interventional Cardiology

FDA Grants R3 Vascular IDE Approval for ELITE-BTK Pivotal Trial Diagnostic and Interventional Cardiology

R3 Vascular Announces $87 Million in Series B Financing and - GlobeNewswire

R3 Vascular Announces $87 Million in Series B Financing and GlobeNewswire

Top R3 Vascular Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant